ByteDance spin-off Anew Labs raises US$290m as AI drug developers enjoy fundraising boom
China is seeing a fresh fundraising boom for AI drug developers, with start-ups including a ByteDance spin-off raising hundreds of millions of dollars this week as investors rush to back domestic challengers to Anthropic and Isomorphic Labs.
Anew Labs, a Shanghai-based AI drug discovery firm that was formerly a unit of Chinese tech giant ByteDance, has raised US$290 million at a valuation of US$1.5 billion, according to an informed source.
Investors included prominent venture capital firms such...
此摘要由5News从媒体的公开信息源汇聚而成。 包含完整背景的全文在www.scmp.com — 内容归South China Morning Post - Business所有。